Prostate Needle Biopsy Biomarker Predicts Tumor Aggressiveness
By LabMedica International staff writers Posted on 11 Apr 2016 |
Image: Schematic diagram of a transrectal prostate biopsy (Photo courtesy National Cancer Institute).
A new study demonstrates the ability to measure and evaluate biomarkers from ribonucleic acid (RNA) expression data obtained from prostate needle biopsies. The data demonstrate a high concordance in the genomic signatures between needle biopsy samples and post-prostatectomy tissue samples.
The study showed that genetic information from prostate needle biopsy may be used to predict tumor aggressiveness and provided preliminary evidence that the Decipher score may be predictive of disease progression following biopsy as well as following prostate surgery and concordance in molecular information between prostate biopsy and surgery samples analyzed.
Scientific collaborators from Cedars Sinai Medical Center (Los Angeles, CA, USA) and other institutions compared analysis of a total of 158 samples from 33 men, including pre-operative needle core biopsies and tissues obtained from radical prostatectomy. The identified 95% of transcriptomic features expressed in surgical samples were expressed in pre-surgery biopsy samples with a high expression correlation. The expression signature pattern yielded by Decipher Biopsy (GenomeDx Biosciences; Vancouver, BC, Canada) showed a high degree of correlation between the two sample types providing strong evidence of the utility of Decipher Biopsy in prostate needle biopsies.
Jeffry Simko, PhD, MD, a Professor of Clinical Pathology, said, “More than 800,000 men undergo prostate biopsy annually in the United States to identify prostate cancer, and this study increases confidence that reliable, quality genomic information can be obtained for those biopsies to better classify patient risk. Genomic biomarkers used by Decipher may help overcome current challenges of tumor heterogeneity and variability in staging of disease. Studies demonstrate that the Decipher score may be predictive of disease progression in diagnostic prostate needle biopsies and warrants a larger, adequately powered study to validate this observation.” The study will be published in the May 2016 issue of Journal of Molecular Diagnostics.
Related Links:
Cedars Sinai Medical Center
GenomeDx Biosciences
The study showed that genetic information from prostate needle biopsy may be used to predict tumor aggressiveness and provided preliminary evidence that the Decipher score may be predictive of disease progression following biopsy as well as following prostate surgery and concordance in molecular information between prostate biopsy and surgery samples analyzed.
Scientific collaborators from Cedars Sinai Medical Center (Los Angeles, CA, USA) and other institutions compared analysis of a total of 158 samples from 33 men, including pre-operative needle core biopsies and tissues obtained from radical prostatectomy. The identified 95% of transcriptomic features expressed in surgical samples were expressed in pre-surgery biopsy samples with a high expression correlation. The expression signature pattern yielded by Decipher Biopsy (GenomeDx Biosciences; Vancouver, BC, Canada) showed a high degree of correlation between the two sample types providing strong evidence of the utility of Decipher Biopsy in prostate needle biopsies.
Jeffry Simko, PhD, MD, a Professor of Clinical Pathology, said, “More than 800,000 men undergo prostate biopsy annually in the United States to identify prostate cancer, and this study increases confidence that reliable, quality genomic information can be obtained for those biopsies to better classify patient risk. Genomic biomarkers used by Decipher may help overcome current challenges of tumor heterogeneity and variability in staging of disease. Studies demonstrate that the Decipher score may be predictive of disease progression in diagnostic prostate needle biopsies and warrants a larger, adequately powered study to validate this observation.” The study will be published in the May 2016 issue of Journal of Molecular Diagnostics.
Related Links:
Cedars Sinai Medical Center
GenomeDx Biosciences
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans